Helping Building Owners Navigate New York’s Local Law 97

The earth’s climate is rapidly changing, and the city of New York is taking groundbreaking action to confront this impending crisis. Through the newly enacted Local Law 97, the city targets one of its most prominent contributors to greenhouse gas emissions: buildings. An ambitious legislative initiative that could influence global urban policy, it plans to slash the city’s carbon footprint by 40% by 2030 and a whopping 80% by 2050. With over 50,000 structures targeted for reform, the implications of Local Law 97 on the real estate landscape of New York are monumental.

But what exactly does the implementation of this law mean for building owners, investors, tenants, and the broader city community? How will this legislation shape the future of the New York real estate industry? Could it signal the beginning of a worldwide urban transformation, and are current strategies available to help building owners meet their sustainability goals – or should they also consider alternative solutions?

In this Roof Talks episode hosted by Michelle Dawn Mooney, she and her two guests, Steven Schleider, Senior Managing Director at JLL Value and Risk Advisory, and Dave Schupmann, COO at Fortis, explore the intricacies and implications related to Local Law 97.

Mooney, Schleider, and Schupmann’s conversation include the following:

  • A comprehensive breakdown of Local Law 97, its goals, and the stakeholders most likely to be impacted
  • The critical role of energy efficiency upgrades and compliance strategies for building owners
  • The expanding role of renewable energy solutions, particularly solar, in achieving emission reduction targets

Steven Schleider brings an impressive portfolio as the Senior Managing Director of JLL Value and Risk Advisory. He is known for his expertise in commercial real estate valuation, consulting, and risk assessment, and his work spans the entire New York Tri-State Region. His vast knowledge and experience in the industry make him a trusted authority on the implications of Local Law 97 on commercial real estate.

Dave Schupmann serves as the Chief Operating Officer at Fortis, a company renowned for its inclusive warranty and Roof Performance Programs. With his deep understanding of operational strategy and his passion for sustainable development, Schupmann offers unique insight into how Local Law 97 can drive the integration of renewable energy solutions in New York’s urban landscape.

Follow us on social media for the latest updates in B2B!

Image

Latest

Doable
Rethinking Leadership: Why “Doable” Might Be the Most Powerful Strategy in Education Today
April 3, 2026

At a time when educator burnout is rising and schools across the U.S. are facing ongoing teacher shortages, leaders are being forced to rethink what sustainable success actually looks like. Research shows that teacher attrition is closely tied to working conditions, job-related stress, and workload demands. As districts push for innovation, data-driven instruction, and…

Read More
Casey Brown
From Poverty to Pricing Power | Why Great Companies Undercharge
April 2, 2026

Casey Brown didn’t grow up thinking she would become an entrepreneur. She grew up in a blue-collar family where money was always tight — close enough to the edge that the fear of poverty shaped many of her early decisions. That fear led her into engineering, into corporate America, and eventually into a moment…

Read More
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
April 2, 2026

In this episode of Care Anywhere, host Lea Sims sits down with Nigerian nurse entrepreneur and advocate Obafemi Arowosegbe to discuss leadership, mentorship, and the future of nursing in Africa. While still a nursing student, Obafemi founded the Nightingale Summit, a growing conference designed to empower nursing students and early-career nurses with leadership skills,…

Read More
Oncology
From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation
April 1, 2026

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…

Read More